| ACE | Angiotensin converting enzyme |
| ACE-I | Angiotensin converting enzyme inhibitor |
| AGT | Angiotensinogen |
| AGTR-1/2 | Angiotensin II receptor 1/2 |
| ARB | Angiotensin receptor blocker |
| AVF | Arterio-venous fistula |
| CI | Confidence interval |
| ESRD | End stage renal disease |
| HTN | Hypertension |
| HD | Hemodialysis |
| HIF-1α | Hypoxia inducible factor-1α |
| HO-1 | Heme oxygenase-1 |
| MMPs | Matrix metalloproteinases |
| MTHFR | Methylene tetrahydrofolate reductase |
| NIH | Neo-intimal hyperplasia |
| OR | Odds ratio |
| PRMT1 | Protein arginine methyltransferase 1 |
| RAAS | Renin-angiotensin-aldosterone system |
| RRT | Renal replacement therapy |
| SNP | Single nucleotide polymorphism |
| TGF-β1 | Transforming growth factor-β1 |
| VEGF-A | Vascular endothelial growth factor-A |
| VEGFR-1/2 | Vascular endothelial growth factor receptor-1/2 |